One hundred nine patients with hepatocellular carcinoma were treated with intravenous (IV) Adriamycin (doxorubicin). Cumulative survival rate was 34% at 6 months and 13% at 1 year. Survival was positively related to a good performance status and to alpha-fetoprotein less than 50 ng/ml, not influenced by hepatitis B surface antigen (HBsAg) and by presence of clear cells in the tumor. Partial response (alpha-fetoprotein decrease by greater than or equal to 50% of the initial value) was observed in 10 patients and complete response in 1 patient, always within the fourth dose, with a 10% response rate. Twenty of 75 symptomatic patients (27%) achieved improvement in performance and/or pain reduction. Withdrawal of treatment became necessary for side effects in six patients. In conclusion, IV Adriamycin in hepatocellular carcinoma has only limited efficacy. Because of its early activity, treatment can be stopped after three doses if there is no evidence of response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/1097-0142(19851215)56:12<2751::aid-cncr2820561205>3.0.co;2-o | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarker Panels Associated with Diagnosis and Overall Survival in Hepatocellular Carcinoma Revealed from Protein-Protein and mRNA-miRNA Interaction Networks.
Asian Pac J Cancer Prev
January 2025
Zanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.
Background: Hepatocellular carcinoma (HCC), the most common form of liver cancer, has a significant mortality rate, largely due to late diagnosis. Recent advances in medical research have demonstrated the potential of biomarkers for early detection. Moreover, the discovery and use of prognostic biomarkers offer a ray of hope in the fight against liver cancer.
View Article and Find Full Text PDFDetection of H-Pylori in the Explanted Liver Tissue and the Enlarged Perihepatic Lymph Nodes of Cirrhotic Patients with Decompensated End-Stage Liver Disease Recruited for Liver Transplantation.
Asian Pac J Cancer Prev
January 2025
Department of Anatomic Pathology, Faculty of Medicine, Kasralainy, Cairo University, Cairo, Egypt.
Background: Helicobacter pylori bacteria colonize the gastric mucosa and contribute to the occurrence and development of gastrointestinal diseases. According to the WHO, H. pylori bacteria are considered class I carcinogen.
View Article and Find Full Text PDFInterleukin-17A and Interleukin-17F Gene Polymorphisms in Egyptian Patients with Chronic Hepatitis C and Hepatocellular Carcinoma.
Asian Pac J Cancer Prev
January 2025
Department of Biochemistry, Biotechnology Research Institute, High Throughput Molecular and Genetic laboratory, Center for Excellences for Advanced Sciences, National Research Centre, Dokki, Giza, Egypt.
Objective: Interleukin IL-17A and IL-17F are critical cytokines involved in inflammatory processes. Genetic variations in IL-17A and IL-17F might be linked to chronic hepatitis C (CHC) and an increased risk of hepatocellular carcinoma (HCC), a cancer associated with long-term inflammation. This study aims to examine the relationship between specific polymorphisms in IL-17A (rs2275913) and IL-17F (rs763780) and their association with HCV-related HCC in an Egyptian population.
View Article and Find Full Text PDFRobotic Anatomical Segment VIII Resection for Hepatocellular Carcinoma Using the Scissor Hepatectomy Technique.
Ann Surg Oncol
January 2025
Department of General and Visceral Surgery, Ulm University Hospital, Ulm, Germany.
Background: Robotic hepatectomy has been increasingly adopted for the treatment of hepatocellular carcinoma (HCC). However, the ideal technique of parenchymal transection in robotic hepatectomy has been a matter of ongoing debate in literature.
Patients And Methods: In this video, we demonstrate the technique of robotic anatomical segment VIII resection using the scissor hepatectomy technique for parenchymal transection on a 75-year-old male patient with a solitary HCC lesion.
Outcome and Prognosis of Invasive Treatment for Hepatocellular Carcinoma in Very Elderly Patients Over 90 Years Old.
Turk J Gastroenterol
January 2025
Department of Gastroenterology and Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Background/Aims: To evaluate invasive treatment outcomes for hepatocellular carcinoma (HCC) in patients aged over 90 years. Materials and methods: Twenty-six patients were included. Information on backgrounds, course of treatment, outcomes, and changes in Child-Pugh (CP) score and performance status (PS), as well as a comparison of treatment-related complications and 2-year survival after treatment, were retrospectively examined and compared with 311 patients aged under 90 years who were matched under the same conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!